Eocene Ltd.
Research Eocene Ltd. (EOCN) on Bullrun: market cap USD 2.74M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEOCN
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.74M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 2.72M
- Free cash flow-USD 2.13M
Valuation Snapshot
latest market cap is USD 2.74M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 10.31M | -USD 6.32M | n/a | -19.12 | USD 3.99M | n/a | USD 15.78M |
| FY2024 | USD 0 | -USD 7.52M | -USD 5.88M | n/a | -64.64 | USD 4.65M | USD 0 | USD 16.33M |
| FY2023 | USD 0 | -USD 6.91M | -USD 6.14M | n/a | -240 | USD 2.86M | USD 41.00K | USD 13.88M |
| FY2022 | USD 0 | -USD 17.87M | -USD 18.51M | n/a | -1022.4 | USD 2.02M | USD 215.00K | USD 13.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 2.74M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.94M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.82M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 12.60M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 45.60M | n/a | n/a | n/a |
About Eocene Ltd.
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Eocene Ltd.'s market cap?
Eocene Ltd.'s market capitalization is USD 2.74M.
What does Eocene Ltd. do?
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.